Literature DB >> 18473774

Pre-emptive conditioning of the ischemic heart.

Joseph M Vitale1, Hongyu Qiu, Christophe Depre.   

Abstract

Ischemic heart disease remains one of the most frequent causes of morbidity and mortality worldwide. Although the prognosis of myocardial ischemia has been dramatically improved by the techniques of early reperfusion, the prevention of irreversible ischemic damage remains a critical aspect of the treatment. An appealing novel therapeutic avenue for the prevention of myocardial ischemia relates to the possibility of a pre-emptive conditioning of the heart, in which an activation of survival pathways could be achieved in patients with ischemic heart disease who are at risk for a subsequent lethal ischemia. These patients would include those with unstable angina, or with severe and repetitive ischemic episodes, and patients scheduled for surgical revascularization. In these situations, the pre-emptive activation of survival signaling mechanisms would confer a prophylactic cardioprotection during the following ischemic stress. During the last twenty years, it became clear that the heart can trigger survival mechanisms when submitted to stress, in such conditions as myocardial stunning, hibernation and preconditioning. The goal of the pre-emptive conditioning is to activate such survival pathways as a prophylactic measure to prevent myocardial cell death when the heart is threatened by potentially lethal ischemia. Based on the experimental data collected at the bench side, we review how this approach could be applied in the clinical setting.

Entities:  

Mesh:

Year:  2008        PMID: 18473774     DOI: 10.2174/187152508783955015

Source DB:  PubMed          Journal:  Cardiovasc Hematol Agents Med Chem        ISSN: 1871-5257


  2 in total

1.  Ubiquitin, a novel paracrine messenger of cardiac cell survival.

Authors:  Dan Li; Christophe Depre
Journal:  Cardiovasc Res       Date:  2010-01-25       Impact factor: 10.787

2.  Preemptive conditioning of the swine heart by H11 kinase/Hsp22 provides cardiac protection through inducible nitric oxide synthase.

Authors:  Li Chen; Paulo Lizano; Xin Zhao; Xiangzhen Sui; Sunil K Dhar; You-Tang Shen; Dorothy E Vatner; Stephen F Vatner; Christophe Depre
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-11       Impact factor: 4.733

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.